Glucagon-Like Peptide-1 Receptor Agonist Mediated Weight Loss and Diabetes Mellitus Benefits: A Narrative Review

Authors

Alan D. Kaye, Louisiana State University Health Sciences Center, Shreveport, LA
Nathan Lien, Louisiana State University Health Sciences Center, Shreveport, LA
Christopher Vuong, LSU Health Sciences Center - New OrleansFollow
Matthew H. Schmitt, Louisiana State University Health Sciences Center, Shreveport, LA
Yusra Soorya, Louisiana State University Health Sciences Center, Shreveport, LA
Bushirat A. Abubakar, Louisiana State University Health Sciences Center, Shreveport, LA
Luke Muiznieks, Louisiana State University Health Sciences Center, Shreveport, LA
Noah Embry, Louisiana State University Health Sciences Center, Shreveport, LA
Harish Siddaiah, Louisiana State University Health Sciences Center, Shreveport, LA
Adam M. Kaye, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA
Sahar Shekoohi, Louisiana State University Health Sciences Center, Shreveport, LA
Giustino Varrassi, Fondazione Paolo Procacci, Rome, ITA

Document Type

Article

Publication Date

12-20-2024

Publication Title

Cureus

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are chronic diseases with increasing prevalence, underscoring the urgent need for effective treatment and management strategies. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as an essential class of drugs for managing both obesity and T2DM, offering additional benefits for cardiovascular and kidney health. GLP-1 RAs work by targeting GLP-1 receptors, mimicking the effects of the natural hormone GLP-1 to regulate blood glucose levels, promote weight loss, and provide potential benefits for cardiovascular health. This narrative review evaluates the mechanisms of action, clinical efficacy, and broader roles of GLP-1 RAs in promoting weight loss and glycemic control. In addition, the present investigation explores recent clinical studies demonstrating the effectiveness of GLP-1 RAs in diabetic and nondiabetic populations, highlighting their potential in addressing obesity even in those without T2DM and describing probable benefits to cardiovascular health. Finally, our investigation outlines the importance of future research to further define the potential benefits of GLP-1 RAs.

First Page

e76101

PubMed ID

39840162

Volume

16

Issue

12

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Recommended Citation

Kaye, Alan D.; Lien, Nathan; Vuong, Christopher; Schmitt, Matthew H.; Soorya, Yusra; Abubakar, Bushirat A.; Muiznieks, Luke; Embry, Noah; Siddaiah, Harish; Kaye, Adam M.; Shekoohi, Sahar; and Varrassi, Giustino, "Glucagon-Like Peptide-1 Receptor Agonist Mediated Weight Loss and Diabetes Mellitus Benefits: A Narrative Review" (2024). School of Medicine Faculty Publications. 3392.
https://digitalscholar.lsuhsc.edu/som_facpubs/3392
10.7759/cureus.76101